Anderson Raymond sold $215K of MNPR
Anderson Raymond sold 3,142 shares of Monopar Therapeutics (MNPR) at an average of $68.35 ($66.16–$70.04, $0.21M total) across 4 trades on 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale reduces the director's ownership but is unlikely to materially affect share price given its modest size.
Market read
Primary insider filing; modest sell‑off may cause slight short‑term pressure but limited trading relevance.
What to watch
Potential upcoming clinical milestones or financing activities that could offset the negative signal.
Background
SEC Form 4 filings disclose insider transactions; this filing reports a director's sale under a pre‑arranged 10b5‑1 plan.
Ticker impact
Director Anderson Raymond sold 3,142 shares for $214,746 via a 10b5-1 plan, reducing his stake to 5,373 shares.
likely slight pressure as the market prices the director's sell-off
Form 4 is a primary source; the transaction size (~$215k) is modest, so any price effect should be limited.
Market effects
Minimal impact on the biotech sector; insider sales are routine and not indicative of broader trends.
No regional effect; the filing is specific to Monopar Therapeutics.
Limited relevance beyond investors tracking MNPR.
Counterpoint
The sale could be unrelated to company fundamentals; investors might view it as a routine liquidity event.
Key entities
- companyMonopar Therapeutics
Biotech firm (ticker MNPR) whose director sold shares.
- personAnderson Raymond
Director of Monopar Therapeutics executing a 10b5‑1 sale.
